Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

The T790M secondary mutation of the epidermal growth factor receptor (EGFR) gene accounts for 50% to 60% of cases of resistance to the first-generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. The prevalence of T790M in EGFR mutation–positive patients who acquire resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Kentaro, Nosaki, Kaname, Otsubo, Kohei, Azuma, Koichi, Sakata, Shinya, Ouchi, Hiroshi, Morinaga, Ryotaro, Wataya, Hiroshi, Fujii, Akiko, Nakagaki, Noriaki, Tsuruta, Nobuko, Takeshita, Masafumi, Iwama, Eiji, Harada, Taishi, Nakanishi, Yoichi, Okamoto, Isamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620242/
https://www.ncbi.nlm.nih.gov/pubmed/28978102
http://dx.doi.org/10.18632/oncotarget.19243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620242/
https://www.ncbi.nlm.nih.gov/pubmed/28978102
http://dx.doi.org/10.18632/oncotarget.19243

Ejemplares similares